key: cord-0957225-6aw6e52o
authors: Lindner, Andreas K.; Krüger, Lisa J.; Nikolai, Olga; Klein, Julian A. F.; Rössig, Heike; Schnitzler, Paul; Corman, Victor M.; Jones, Terry C.; Tobian, Frank; Gaeddert, Mary; Burock, Susen; Sacks, Jilian A.; Seybold, Joachim; Mockenhaupt, Frank P.; Denkinger, Claudia M.
title: SARS-CoV-2 Variant of Concern B.1.1.7: Diagnostic Sensitivity of Three Antigen-Detecting Rapid Tests
date: 2022-01-05
journal: Microbiol Spectr
DOI: 10.1128/spectrum.00763-21
sha: c75e9b13da1136d9b950919f256d4640941f99cd
doc_id: 957225
cord_uid: 6aw6e52o

nan

(registration number EA1/371/20) and of the Heidelberg University Hospital (registration number S-180/2020).

Of 1,692 adults enrolled in the study, 354 (21%) tested positive by RT-PCR. Positive samples were typed for the N501Y and del69-70 polymorphisms by melting curve analysis. The presence of both polymorphisms was considered indicative of a B.1.1.7 lineage infection, an inference whose accuracy was confirmed by full-genome sequencing of all Heidelberg samples. For 22 patients (6%), typing was not done or was not possible due to the limit of detection of genotyping for samples with low viral loads (excluded from analysis). During the study, B.1.1.7 became the dominant SARS-CoV-2 lineage within only 5 weeks (12) . Among the positive patients, 220 (62%) were infected with B.1.1.7, 3 (1%) with variant of concern (VOC) B.1.351, and 109 (31%) with other non-B.1.1.7 lineages. Three positive patients with viral typing results were excluded from the analysis due to invalid Ag-RDT results. Of the 329 positive patients included in the analysis, the majority (92.1%) were symptomatic. All three Ag-RDTs yielded comparable sensitivities, irrespective of an infection with the B.1.1.7 lineage (Table 1) .

Sensitivities are overestimated due to the limit of detection of genotyping for samples with low viral loads. Furthermore, the study is limited by the rapid emergence of the B.1.1.7 lineage during the course of the study, which led to an unequal distribution of this variant among the three Ag-RDTs. This did not allow a subanalysis by viral load, which could have potentially unmasked differences among the Ag-RDTs at low viral loads. Also, the study results are limited to mainly symptomatic patients.

There are only limited data on how N-gene mutations in VOCs may impact Ag-RDTs, and this study provides a clinical evaluation that complements analytical evaluations (6, 8, (13) (14) (15) (16) . To date, no major changes in test performance have been anticipated (7) . However, test developers and health authorities should assess and monitor the impact of emerging variants on Ag-RDTs during development and postauthorization (17) .

Data availability. All raw data and analysis code are available upon a request to the corresponding author.

We acknowledge Chiara Rohardt, Maximilian Gertler, Elisabeth Linzbach, Domenika Pettenkofer, Christian Schönfeld, and Julian Bernhard. 

Threat assessment brief: rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom

Weekly epidemiological update on COVID-19: 1

Centers for Disease Control and Prevention. 2021. COVID-19 data tracker weekly review

Bericht zu Virusvarianten von SARS-CoV-2 in Deutschland

Weekly epidemiological update on COVID-19: 23

SARS-CoV-2 lateral flow antigen tests: evaluation of VOC1 (Kent, UK) and VOC2 (South Africa

Foundation for Innovative New Diagnostics. 2021. SARS-CoV-2 variants

SARS-CoV-2 lateral flow antigen tests: evaluation of VUI-202012/01

Foundation for Innovative New Diagnostics. 2021. FIND evaluation of SARS-CoV-2 antigen (Ag) detecting tests

Accuracy of the Mologic COVID-19 rapid antigen test: a prospective multicentre analytical and clinical evaluation

The Abbott PanBio WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2: evaluation of the accuracy and ease-of-use

Emergence of SARS-CoV-2 B.1.1.7 lineage at outpatient testing site

CoV-2-Public Health Laboratory Team, Bavarian SARS-CoV-Public Health Laboratory Team. 2021. Detection of the new SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV-2 rapid antigen tests (RATs)

SARS-CoV-2 rapid diagnostic tests for emerging variants

Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study

Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR

Policy for evaluating impact of viral mutations on COVID-19 tests